Conference Call & Webcast
Thursday, May 14, 2015 at 8:30 a.m. ET/5:30 a.m. PT
Domestic: 888-299-7209
International: 719-325-2244
Conference ID: 9028301
Webcast: http://public.viavid.com/player/index.php?id=114583
Replay
Available through May 28, 2015
Domestic: 877-870-5176
International: 858-384-5517
Conference ID: 9028301
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn™ has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
Media: Tony Fiorino, MD, PhD, Chief Executive Officer, BrainStorm Cell Therapeutics Inc., 201-488-0460, info@brainstorm-cell.com; or Investors: Michael Wood, LifeSci Advisors, LLC, 646-597-6983, mwood@lifesciadvisors.com